Loading market dashboard
Abivax S.A.
ABVXHealthcareNASDAQFR
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
New York, New York--(Newsfile Corp. - June 4, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into ABIVAX Societe Anonyme ("ABIVAX Societe Anonyme") (NASDAQ: ABVX) concerning potential violations of the federal securities laws. Abivax shareholders lost more than 40% of their investment value on June 2, 2026, as the stock plunged from a pre-announcement close of approximately $129.69 to as low as $71 per share midday after rare malignancy cases surfaced in the company's Phase 3 ABTECT ulcerative colitis trial for obefazimod.
[url="]The Schall Law Firm[/url], a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Abivax S.A
LOS ANGELES--(BUSINESS WIRE)---- $ABVX--ABVX Investors Have Opportunity to Join Abivax S.A. Fraud Investigation with the Schall Law Firm.
The heavy selling pressure might have exhausted for Abivax SA Sponsored ADR (ABVX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Abivax Investigation Initiated: SueWallSt Investigates the Officers and Directors of Abivax (ABVX) PR Newswire N
Jefferies downgraded Abivax from Buy to Hold and slashed its price target by nearly 44% after rare cancer cases emerged in the company's Phase 3 ulcerative colitis trial -- shares more than 40% of their value in a single session. NEW YORK, June 2, 2026 /PRNewswire/ -- Abivax (NASDAQ: ABVX) shareholders more than to 40% of their investment value on June 2, 2026, as the stock plunged from a pre-announcement close of approximately $129.69 to as low as $71 per share midday after rare malignancy cases surfaced in the company's Phase 3 ABTECT ulcerative colitis trial for obefazimod.
Abivax SA (ABVX) was hit hard after cancer cases in a pivotal trial created a fresh cloud over obefazimod, the French biotech's lead drug for moderately to seve
ABIVAX Société Anonyme (ABVX) Discusses Positive Phase III ABTECT Trial Results for Obefazimod in Ulcerative Colitis Transcript
Pre-Market Stock Futures: Futures are trading lower on Tuesday, but the technology tsunami continued on Monday, as all major indices dipped into the red early on news that Iran was halting the peace negotiations and would block the Strait of Hormuz. But that sell-off lasted until about noon, before a big reversal, which, by that... Here Are Tuesday's Top Wall Street Analyst Research Calls: CoreWeave, Danaher, Hewlett Packard Enterprise, Intuit, Knight-Swift, Meta Platforms, Starwood Property Trust, Tripadvisor, and More
The biotech said some patients developed cancer in a late-stage clinical trial for the bowel-disease drug that were unrelated to the treatment.
Abivax shares fell 31% even after the French biotech reported strong late-stage data for obefazimod, its experimental treatment for ulcerative colitis. The once-daily oral therapy met the main goal and all key secondary endpoints in a Phase 3 maintenance study, strengthening the case for a potential new option in a market still led by injectable biologics and other advanced treatments.
Abivax shares tumbled on Tuesday after the French biotech reported late-stage data for its experimental inflammatory bowel drug, with investors focusing on safety concerns even as the treatment showed strong efficacy.
Biotech takeover target Abivax sinks over 30% after bowel disease drug trial update
Abivax said on Monday its experimental drug for patients with ulcerative colitis, a type of chronic inflammatory disease, met the main goal of a closely watched late-stage trial.
Abivax stock crashed Monday after several patients developed cancer following a study of its ulcerative colitis treatment.
Abivax Announces Landmark Phase 3 ABTECT Maintenance Trial Results Evaluating Obefazimod in Moderately to Severely Active Ulcerative Colitis
Does Abivax SA Sponsored ADR (ABVX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Abivax Presents First Quarter 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients with Ulcerative Colitis
Abivax Announces Repurchase of Royalty Certificates and Pricing of $45M (€38.5M) Offering of American Depositary Shares
Shares of Abivax SA Sponsored ADR (NASDAQ: ABVX - Get Free Report) have been given an average rating of "Moderate Buy" by the fifteen analysts that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, thirteen have assigned a buy recommendation and one has issued a strong
Abivax to Present Data on Obefazimod at Digestive Disease Week ® Presentations Highlight Comprehensive Efficacy, Safety, and Patient-Reported Outcomes from the Phase 3 ABTECT Program and Preclinical Anti-Fibrotic Models in Inflammatory Bowel Disease PARIS, France – April 22, 2026 – 10:05 pm CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced that nine scientific abstracts on obefazimod, its lead drug candidate for the treatment of moderately to severely active ulcerative colitis (UC), will be presented at the 2026 Digestive Disease Week (DDW) taking place May 2-5, 2026 in Chicago, IL. These presentations will highlight data from the Phase 3 ABTECT program, including efficacy, safety, and patient-reported outcomes, along with preclinical anti-fibrotic activity in two preclinical fibrosis models.
Abivax Annual Ordinary and Extraordinary General Meeting of May 11, 2026 Availability of the Preparatory Documents
Abivax's leading candidate looks very promising. However, between potential clinical setbacks and the biotech's high market cap, the stock looks risky.
Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies Abivax publishes financial reports with the French and U.S. securities regulatory agencies PARIS, France – April 1, 2026 – 10:05 PM CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, announces the filing of its Universal Registration Document (Document d'Enregistrement Universel) with the French Financial Market Authorities, Autorité des Marchés Financiers (AMF), and the filing of its Annual Report (20-F) with the U.S. Securities and Exchange Commission (SEC) on March 23, 2026. The Universal Registration Document includes the 2025 annual financial report, the management report including the report on corporate governance, as well as the reports of the statutory auditors.
Abivax remains a buy, with Obefezimod showing best-in-class efficacy and safety in ulcerative colitis and potential in Crohn's disease. Updated phase 3 and UEG safety data further de-risk ABVX, supporting earlier line use and expanding market potential beyond refractory patients. I raise my probability of success to 95%, increasing the 12-month target price to $140 per share, reflecting ~25% upside.
These two biotechs could ride the wave of significant clinical progress. However, both carry above-average risk.
• Abivax stock is taking a hit today. Why is ABVX stock falling?
Abivax CEO Marc de Garidel told CNBC that the terms of any future deal will be better after it releases data on a key trial in the second quarter. Intense takeover rumors have surrounded the French biotech company for months, with analysts seeing it as a prime takeover target.
Abivax is viewed as a buyout candidate thanks to its promising lead drug candidate, obefazimod. Abivax is testing obefazimod for multiple conditions.
Bamco Inc. NY acquired a new stake in Abivax SA Sponsored ADR (NASDAQ: ABVX) in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 14,000 shares of the company's stock, valued at approximately $1,189,000. Several other large investors have also recently made
Abivax remains a 'Strong Buy' due to obefazimod's positive phase 3 UC data and upcoming pivotal maintenance results in late Q2 2026. Company's differentiated mir-124 enhancer mechanism targets both inflammatory and fibrotic pathways, positioning it uniquely in the IBD therapeutic landscape. Key catalysts include 44-week phase 3 UC maintenance data and phase 2b Crohn's Disease induction results, both expected in 2026.
Biotechnology company Abivax dismissed information published by French media publication "La Lettre" saying it had granted AstraZeneca exclusive access to confidential information until March 23 to allow the British pharmaceutical giant to formalise a takeover offer.
British drugmaker AstraZeneca Plc (NYSE: AZN) has emerged as the leading contender to acquire French biotech Abivax SA (NASDAQ: ABVX), following the company's dramatic valuation surge after strong clinical progress tied to its lead drug candidate.
Revolution Medicines was a top contributor during the quarter. AbbVie, by contrast, traded largely sideways, as investors continued to assess its post-patent earnings durability. While Eli Lilly delivered strong absolute performance — driven by continued GLP-1 demand and the FDA approval of Zepbound — our underweight position in the name was a significant detractor from relative results. During the quarter, we purchased Avidity Biosciences, a clinical-stage biopharma company focused on RNA therapies for rare muscle diseases, and Abivax SA, a clinical-stage biopharma company focused on chronic inflammatory diseases.
Is there any upside left for this rising biotech?
